Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 18;17(10):91.
doi: 10.1007/s11892-017-0926-8.

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Patrick F Frias  1 , Juan Pablo Frias  2
Affiliations
Review

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Patrick F Frias et al. Curr Diab Rep. .

Abstract

Purpose of review: The purpose of this review was to review advances in basal insulin formulations and new treatment options for patients with type 2 diabetes not achieving glycemic _targets despite optimized basal insulin therapy.

Recent findings: Advances in basal insulin formulations have resulted in products with increasingly favorable pharmacokinetic and pharmacodynamic properties, including flatter, peakless action profiles, less inter- and intra-patient variability, and longer duration of activity. These properties have translated to significantly reduced risk of hypoglycemia (particularly during the night) compared with previous generation basal insulins. When optimized basal insulin therapy is not sufficient to obtain or maintain glycemic goals, various options exist to improve glycemic control, including intensification of insulin therapy with the addition of prandial insulin or changing to pre-mixed insulin and, more recently, the addition of a GLP-1 receptor agonist, either as a separate injection or as a component of one of the new fixed-ratio combinations of a basal insulin and GLP-1 RA. New safer and often more convenient basal insulins and fixed ratio combinations containing basal insulin (and GLP-1 receptor agonist) are available today for patients with type 2 diabetes not achieving glycemic goals. Head-to-head studies comparing the latest generation basal insulins are underway, and future studies assessing the fixed-ratio combinations will be important to better understand their differentiating features.

Keywords: Basal insulin; Fixed-ratio combination; GLP-1 receptor agonists; Type 2 diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Diabetes Obes Metab. 2015 Apr;17(4):386-94 - PubMed
    1. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
    1. Diabetes Obes Metab. 2015 Aug;17(8):734-41 - PubMed
    1. Pharm Res. 2004 Aug;21(8):1498-504 - PubMed
    1. Diabetes Care. 2015 Apr;38(4):637-43 - PubMed

MeSH terms

LinkOut - more resources

  NODES
twitter 2